Dwarfism: Clinical Trials

20 trials for Dwarfism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed. 20 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 120Completed 20
Phase 24Completed 4

Follow Dwarfism: new trials by email Literature Review of Dwarfism trials Research Report on Dwarfism

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects
somapacitan - Healthy Volunteers, Growth Hormone Deficiency
Phase 1CompletedNovo Nordisk A/S332019-03-292019-08-06
Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency
Norditropin - Short Stature
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati222018-02-012024-07-30
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency
Phase 1CompletedNovo Nordisk A/S342017-08-162019-05-24
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency
Phase 1CompletedNovo Nordisk A/S442017-06-202020-04-17
IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency
Increlex - Short Stature
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati72015-12-212024-02-28
Pappalysin 2 (PAPP-A2) Enzyme Replacement
Fresh Frozen Plasma - Short Stature, Idiopathic
Phase 1CompletedChildren's Hospital Medical Center, Cincinnati12015-04-012015-05-28
Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
MOD-4023, Placebo - Growth Hormone Deficiency
Phase 1CompletedOPKO Health, Inc.422015-01-012019-09-30
Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg - Growth Hormone Deficiency
Phase 1CompletedAileron Therapeutics, Inc.332013-01-012013-05-30
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
somapacitan, Norditropin NordiFlex® - Growth Hormone Disorder, Adult Growth Hormone Deficiency
Phase 1CompletedNovo Nordisk A/S352012-10-122020-12-24
Versartis Trial in Children to Assess Long-Acting Growth Hormone
Experimental: VRS-317 - Pediatric Growth Hormone Deficiency
Phase 1 / Phase 2CompletedVersartis Inc.642012-10-012022-07-26
A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers
BMN 111, Normal Saline - Achondroplasia
Phase 1CompletedBioMarin Pharmaceutical742012-02-012012-06-11
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
somapacitan, placebo (somapacitan) - Growth Hormone Disorder, Adult Growth Hormone Deficiency
Phase 1CompletedNovo Nordisk A/S1052012-01-162020-12-24
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
Somatropin, Placebo - Growth Hormone Deficiency
Phase 1CompletedHanAll BioPharma Co., Ltd.402011-09-012012-10-16
VRS-317 in Adult Subjects With Growth Hormone Deficiency
VRS-317 - Growth Hormone Deficiency
Phase 1CompletedVersartis Inc.502011-03-012012-07-23
Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome
Prodarsan - Cockayne Syndrome
Phase 1 / Phase 2CompletedDNage B.V.52010-06-012011-06-23
Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children
somatropin AQ, pegylated somatropin - Growth Hormone Deficiency
Phase 1CompletedChangchun GeneScience Pharmaceutical Co., Ltd.122010-03-012012-06-14
r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial
r-hGH liquid (Saizen), r-hGH freeze-dried - Growth Failure, Growth Hormone Deficiency
Phase 1CompletedEMD Serono302008-07-012013-10-23
A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency
hGH-ViaDerm™ System (hGH or somatropin), hGH-ViaDerm™ System - Growth Hormone Deficiency
Phase 1CompletedTeva Neuroscience, Inc.602007-04-012013-09-02
Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency
Syntropin - Growth Hormone Deficiency
Phase 1CompletedPhage Pharmaceuticals, Inc.202004-08-012012-03-12
A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin
somatropin, placebo - Growth Hormone Disorder, Adult Growth Hormone Deficiency
Phase 1CompletedNovo Nordisk A/S862000-04-062017-02-27

Narrower conditions

Dwarfism, Pituitary (15)  ·  Achondroplasia (1)  ·  Bone Diseases (1)  ·  Bone Diseases, Developmental (1)  ·  Bone Diseases, Endocrine (1)  ·  Brain Diseases (1)  ·  Cockayne Syndrome (1)  ·  DNA Repair-Deficiency Disorders (1)  ·  Failure to Thrive (1)  ·  Genetic Diseases, Inborn (1)  ·  Hypopituitarism (1)  ·  Musculoskeletal Diseases (1)  ·  Pituitary Diseases (1)

Broader conditions

Bone Diseases (19)  ·  Bone Diseases, Developmental (19)  ·  Endocrine System Diseases (19)  ·  Musculoskeletal Diseases (19)  ·  Nervous System Diseases (16)  ·  Central Nervous System Diseases (15)  ·  Hypothalamic Diseases (15)  ·  Bone Diseases, Endocrine (14)  ·  Brain Diseases (14)  ·  Hypopituitarism (14)  ·  Pituitary Diseases (14)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Genetic Diseases, Inborn (5)  ·  Abnormalities, Multiple (1)

Interventions

Human Growth Hormone (6)  ·  somapacitan (5)  ·  NNC0195-0092 (2)  ·  Growth Hormone (1)  ·  Growth Hormone-Releasing Hormone (1)  ·  Growth and Development (1)  ·  Hormone Replacement Therapy (1)  ·  Hormones (1)  ·  Hormones, Hormone Substitutes, and Hormone Antagonists (1)  ·  Insulin-Like Growth Factor Binding Protein 3 (1)  ·  Insulin-Like Growth Factor I (1)  ·  MOD-4023 (1)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (U.S.) (1)  ·  Pharmacokinetics (1)  ·  Saline Solution (1)

Sponsors

Novo Nordisk A/S (6)  ·  Children's Hospital Medical Center, Cincinnati (3)  ·  Versartis Inc. (2)  ·  Aileron Therapeutics, Inc. (1)  ·  BioMarin Pharmaceutical (1)  ·  Changchun GeneScience Pharmaceutical Co., Ltd. (1)  ·  DNage B.V. (1)  ·  EMD Serono (1)  ·  HanAll BioPharma Co., Ltd. (1)  ·  OPKO Health, Inc. (1)  ·  Phage Pharmaceuticals, Inc. (1)  ·  Teva Neuroscience, Inc. (1)

Countries

United States (10)  ·  Germany (4)  ·  Denmark (1)  ·  Slovakia (1)  ·  South Korea (1)  ·  Sweden (1)

Top investigators

Philippe Backeljauw, MD (2)  ·  Andrew Dauber, MD (1)  ·  Bradley D Vince, D.O. (1)  ·  Edward Neilan, MD (1)  ·  Gajanathan Muthuvel, MD (1)  ·  Hubert C Chen, M.D. (1)  ·  Kyung-Sang Yu, Medicine (1)  ·  Luo Xiaoping, Doctor (1)  ·  Mark Kipnes, MD (1)  ·  Michael Lissy, MD (1)  ·  Noa Avisar, PhD (1)

Results publications

PMID 29671202, PMID 33754315, PMID 20961422, PMID 23585663, PMID 25013997, PMID 26727076, PMID 29029190, PMID 33864240, PMID 34922359, PMID 35001504, PMID 36646053, PMID 38969919

NIH funding

2016 (2), 2018 (1)